BASEL, Switzerland, July 24 --

- Not For US Media

- Set to Become First Medicine in EU to Treat Patients Aged Four and Older
Suffering From Life-Long Cryopyrin-Associated Periodic Syndrome (CAPS)(1)

- Ilaris Targets Interleukin-1 Beta (IL-1 Beta), a key Driver of
Inflammation(1,2,3) - Studies Ongoing in Other Diseases Involving IL-1 Beta Such
as Gout, COPD and Type 2 Diabetes

- EU Opinion Follows US and Swiss Approvals Based on Data Showing Ilaris
Produced Rapid and Sustained Remission in CAPS Patients After one Dose(2)

- CAPS Comprises Three Disorders of Increasing Severity With Potentially Fatal
Complications(2,3) - Most Patients Suffer From Severe and Disabling

The biotechnology medicine Ilaris(R) (canakinumab) has passed another major
milestone with a recommendation for approval in the European Union to treat
patients with a life-long and potentially fatal auto-inflammatory disease called
cryopyrin-associated periodic syndrome (CAPS). When approved, Ilaris will be the
only treatment in the EU indicated for CAPS patients aged four years and

Ilaris represents an important advance in the development of personalized
medicines because it targets a condition that is triggered by a specific genetic
mutation. In CAPS patients, this mutation drives the overproduction of
interleukin 1-beta (IL-1 Beta) which causes the widespread sustained
inflammation and tissue damage associated with the disease(3,4,5).

Because Ilaris normalizes the production of IL-1 Beta(1,2,3), it is also being
studied in other diseases in which IL-1 Beta plays a pivotal role such as
systemic juvenile idiopathic arthritis (SJIA), gout, chronic obstructive
pulmonary disorder (COPD), and type 2 diabetes.

By concentrating initially on a rare syndrome with a well-defined disease
process such as CAPS, we have been able to demonstrate a clear therapeutic
advantage with Ilaris, said Trevor Mundel, MD, Head of Global Development at
Novartis Pharma AG. Our focus now is to establish whether this could also
provide a new approach to the treatment of other diseases involving a similar
underlying process.

A positive opinion recommending the approval of Ilaris for CAPS was issued by
the Committee for Medicinal Products for Human Use (CHMP), which reviews
medicines for the European Commission. The recommendation comes shortly after
approvals in the US and Switzerland where Ilaris was granted priority review,
based on its potential to fulfil an important unmet need for CAPS patients.

The EU submission was supported by data showing that Ilaris, a monoclonal
antibody formerly known as ACZ885, produced rapid and sustained remission of
symptoms in up to 97% of CAPS patients, with most responding from the first

Ilaris is given by subcutaneous injection only once every two months, making it
a convenient treatment, especially for younger patients(2). More than 90% of
patients studied were free from painful injection-site Reactions(2).

CAPS includes three distinct auto-inflammatory disorders. These are familial
cold auto-inflammatory syndrome (FCAS) which is the mildest form of CAPS,
Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease
(NOMID, also known as chronic infantile neurological cutaneous articular
syndrome or CINCA) - the most severe form of the disease(2,3).

CAPS is a life-long and potentially fatal condition for which there are
currently no approved medications in the European Union, said Helen J. Lachmann,
MD of the UK National Amyloidosis Centre at UCL Medical School in London, UK. In
clinical trials, canakinumab has been shown to switch off disease activity in as
little as 24 hours following a single dose. It has the potential to transform
patients’ lives, not only providing relief from their debilitating daily
symptoms but also offering the possibility of long-term control of the disease.

The symptoms of CAPS, such as debilitating fatigue, rash, fever, headaches,
joint pain and conjunctivitis, can be present from birth or infancy, and can
occur daily throughout patients’ lives(2,3). Serious long-term
consequences may include deafness, bone deformities, erosive joint destruction,
and central nervous system damage leading to loss of vision(1,2,3). Around 25%
of CAPS patients develop amyloidosis, a condition in which the build-up of
proteins can cause vital organs to fail, resulting in renal failure and death
within five to 10 years(1).

CAPS is believed to occur in around 6,500 patients worldwide and 2,500 in the
EU(3,6). However due to lack of diagnosis or misdiagnosis, fewer than 1,000
cases have been officially reported worldwide(1,3).

The Ilaris filing was based on a clinical trial program involving more than 100
CAPS patients. The pivotal study is a three-part, one-year Phase III study
involving 35 patients aged nine to 74 years old with varying degrees of disease
severity(2). Data published in The New England Journal of Medicine in June 2009
show that Ilaris produced a rapid, complete and sustained response in the
majority of patients(2).

Results for the primary end point showed that none of the patients treated with
Ilaris (0 out of 15) experienced a disease outbreak or ’flare’
compared to 13 of the 16 patients who received placebo (0% vs 81% respectively,

In general, Ilaris was well tolerated with no consistent pattern of adverse
events apart from a slight increase in infections(2). Two patients experienced
serious adverse events, namely a lower urinary tract infection and vertigo(2).
The most common adverse events reported in Ilaris-treated patients were
nasopharyngitis, diarrhea, influenza, headache and nausea(2).

No impact on the type or frequency of adverse events was seen with longer-term
treatment(2). Ilaris was not associated with any severe reactions at the
injection site, and those that did occur were mild-to-moderate in nature(2).

The CHMP recommended approval under exceptional circumstances, granted when
comprehensive data are not yet available due to the rarity of the disease or
limited scientific knowledge. The approval is subject to certain obligations for
the company and is re-assessed each year until normal approval can be given.

Ilaris was approved in Switzerland in July 2009 to treat all three forms of
CAPS in adults and children over four years old, and in the US in June 2009 to
treat two forms of CAPS, namely FCAS and MWS. A study in NOMID patients is under
way in the US and priority reviews are being conducted in other countries,
including Australia and Canada.

In addition to orphan drug status for CAPS, Ilaris has also been designated as
an orphan drug for treating systemic juvenile idiopathic arthritis (SJIA) in the
US, EU and Switzerland, and has fast-track status for SJIA in the US. Orphan
drugs are those developed to treat diseases affecting fewer than 200,000 people
(in the US)(7) or fewer than five out of 10,000 people (in the EU)(8).


The foregoing release contains forward-looking statements that can be
identified by terminology such as potentially, will, could, potential, can, may,
or similar expressions, or by express or implied discussions regarding potential
future regulatory filings or marketing approvals for Ilaris, or the timing of
any such potential filings or approvals, or regarding potential future revenues
from Ilaris. You should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of the Company regarding
future events, and involve known and unknown risks, uncertainties and other
factors that may cause actual results with Ilaris to be materially different
from any future results, performance or achievements expressed or implied by
such statements. There can be no guarantee that Ilaris will be approved for sale
in any additional market, or for any additional indication, or that any such
approvals will occur at any particular time. Nor can there be any guarantee that
Ilaris will achieve any levels of revenue in the future. In particular,
management’s expectations regarding Ilaris could be affected by, among
other things, unexpected clinical trial results, including unexpected new
clinical data and unexpected additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally; the
company’s ability to obtain or maintain patent or other proprietary
intellectual property protection; competition in general; government, industry
and general public pricing pressures; the impact that the foregoing factors
could have on the values attributed to the Group’s assets and liabilities
as recorded in the Group’s consolidated balance sheet, and other risks and
factors referred to in Novartis AG’s current Form 20-F on file with the US
Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Novartis is providing the information in this press release as of
this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

About Novartis

Novartis provides healthcare solutions that address the evolving needs of
patients and societies. Focused solely on healthcare, Novartis offers a
diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and
consumer health products. Novartis is the only company with leading positions in
these areas. In 2008, the Group’s continuing operations achieved net sales
of US$ 41.5 billion and net income of US$ 8.2 billion. Approximately US$ 7.2
billion was invested in RD activities throughout the Group. Headquartered in
Basel, Switzerland, Novartis Group companies employ approximately 99,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit


1. National Horizon Scanning Centre. Canakinumab for cryopyrin associated
periodic syndrome. November 2008. Available at:
dec/Canakinumab.pdf Last accessed April 21, 2009.

2. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of Canakinumab
in the Cryopyrin-Associated Periodic Syndrome. N Engl J Med, 360;23. June 4,

3. Durrant KLW, Goldbach-Mansky R, Hoffman H, Leslie K, Rubin B. CAPS
Cryopyrin-Associated Periodic Syndromes 2008. Available at: Last accessed April 19, 2009.

4. Joost PH, Drenth MD, Jos W.M. van der Meer. The Inflammasome - A Linebacker
of Innate Defense. N Engl J Med 2006. Vol 355:730-732. Number 7.

5. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1 in
patients with cryopyrin-associated periodic syndromes. J Exp Med 2009. Published
online April 13, 2009. Available at:

6. European Medicines Agency (EMEA). Pre-authorisation evaluation of medicines
for human use. Committee for orphan medicinal products. Available at: Last accessed
14 July 2009.

7. Orphan Drug Act. US Food and Drug Administration. Section 526 (2).

8. The orphan drug strategy. Europa: Gateway to the European Union. Paragraph
1, Line 1.

BASEL, Switzerland, July 24 --

SOURCE: Novartis

Novartis Media Relations: Eric Althoff, Novartis Global Media Relations,
+41-61-324-7999, (direct),+41-79-593-4202 (mobile),;
Irina Ferluga, Novartis Pharma, Communications, +41-61-324-2422 (direct),
+41-79-824-1121 (mobile),; e-mail: Novartis Investor Relations: Central phone:
+41-61-324-7944; Ruth Metzler-Arnold, +41-61-324-9980; Pierre-Michel,
+41-61-324-1065; Bringer John Gilardi, +41-61-324-3018; Thomas Hungerbuehler,
+41-61-324-8425; Isabella Zinck, +41-61-324-7188; e-mail: North America: Richard Jarvis, +1-212-830-2433;
Jill Pozarek, +1-212-830-2445; Edwin Valeriano, +1-212-830-2456; e-mail: